NRC Health (NRC) Stock Price & Analysis
NRC Health (NRC) closed at USD 21.38 on Thursday, October 22, 2026, up 5.27% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 20.31; the Oct 22, 2026 session ranged USD 20.32–21.43 on volume of 70,067 shares. Market capitalization is $472.92M, with a 52-week range of USD 11.32–23.68 (NMS). Source: Nexqual, retrieved October 23, 2026 at 12:51 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NRC.md
Key facts (NRC)
- Last four reported quarters (through Jun 30, 2026): revenue $140M, net income $5.9M (4.2% margin), free cash flow $21.6M (SEC filings).
- Valuation: P/E 80.7x (avg 28.2x at the last 3 fiscal year-ends), EV/EBITDA 23.9x, net debt $86.7M.
- Earnings quality: non-operating income -$5.4M vs operating income $14.7M over the last four quarters; P/E excluding non-operating income ≈50.6x (estimate: non-operating income taxed at the company's 35% effective rate).
- Analysts: Strong Buy (mean 1.00 on a 1–5 scale) (1 analysts), mean target USD 26 (range 26–26).
- Total return with dividends: 1Y +89.6% vs S&P 500 +14.9%; 5Y -43.5% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 0.21, revenue estimate $35.8M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NRC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $148M | $152M | $149M | $143M | $137M | $140M |
| Operating income | $50.3M | $46.5M | $40.0M | $35.2M | $22.6M | $14.7M |
| Net income | $37.5M | $31.8M | $31.0M | $24.8M | $11.6M | $5.9M |
| EPS (diluted) | $1.46 | $1.27 | $1.25 | $1.04 | $50.00 | — |
| Free cash flow | $40.8M | $26.4M | $22.3M | $19.2M | $15.7M | $21.6M |
| Operating margin | 34.0% | 30.7% | 27.0% | 24.6% | 16.4% | 10.5% |
| Net margin | 25.3% | 21.0% | 20.8% | 17.3% | 8.4% | 4.2% |
| Revenue growth | +11.0% | +2.4% | -2.0% | -3.7% | -4.0% | — |
| Cash + short-term investments | $54.4M | $25.0M | $6.7M | $4.2M | $4.1M | — |
| Total debt | $26.6M | $22.3M | $36.8M | $57.9M | $79.0M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NRC)
P/E 80.7x · P/E ex non-operating (est.) ≈50.6x · P/S 3.4x · EV/EBITDA 23.9x · EV/Sales 4.0x · P/FCF 21.9x · P/B 72.2x · FCF yield 4.58% · Earnings yield 1.24% · Dividend yield (paid, TTM) 2.69% · Buyback yield (TTM) 3.99% · Net debt $86.7M · EV $560M
P/E at fiscal year-ends: Dec 2025 36.2x, Dec 2024 16.9x, Dec 2023 31.5x.
Analysts (NRC)
Consensus Strong Buy (mean 1.00 on a 1–5 scale), 1 analysts; mean target USD 26 (low 26, high 26).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-29 | Citizens | Target raised | Market Outperform | $23 → $26 |
Total return (dividends reinvested) (NRC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +89.6% | -43.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +90.0% | -10.8% |
| Volatility (annualized) | 59.5% | 42.4% |
| Max drawdown | -46.5% (Jan 2026→Feb 2026) | -76.5% (Nov 2021→Apr 2025) |
NRC company outlook (results filed Jul 28, 2026)
- “It represents the total annualized contract value under customer contracts that are in effect or contractually committed as of the most recent quarter-end, based on contractual pricing and term provisions, and expected to be in force over the subsequent 12 months.”
- “For the three and six months ended June 30, 2026, these costs consist of bonuses paid to certain executives to cover anticipated tax obligations in connection with amendments to their 2025 equity awards, as previously disclosed, and approximately $270,000 of severance costs incurred in connection with team restructurings implemented by newly appointed executives.”
Quoted word-for-word from the SEC 8-K results press release.
NRC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.21 | $0.00 | — | $35.8M | 1 |
| Next quarter (ends Dec 2026) | $0.25 | $0.00 | — | $36.6M | 1 |
| Current fiscal year (ends Dec 2026) | $0.33 | $0.00 | — | $142.6M | 1 |
| Next fiscal year (ends Dec 2027) | $1.05 | $0.00 | — | $154.5M | 1 |
Key Statistics (as of October 23, 2026 at 12:51 UTC)
| Price | USD 21.38 |
|---|---|
| Change | ▲ 5.27% (up) |
| Previous Close | USD 20.31 |
| Open | USD 20.32 |
| Day Range | USD 20.32 – 21.43 |
| 52-Week Range | USD 11.32 – 23.68 |
| Volume | 70,067 shares |
| Market Cap | $472.92M |
| Exchange | NMS |
Technical Analysis (NRC)
Nexqual's technical model rates NRC "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 12:51 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.76 (neutral) |
| vs SMA50 | Above (USD 21.08) |
| MACD | -0.07 (negative) |
Analyst Ratings (NRC)
Wall Street analysts rate NRC "Strong Buy" based on 1 analysts, with a mean price target of USD 26 (range USD 26–26), per Nexqual as of October 23, 2026 at 12:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 26 |
| High Target | USD 26 |
| Low Target | USD 26 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (NRC)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD 0.21 |
| Revenue Estimate | $35.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.31 vs est 0.14 ▲ beat |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financials & Fundamentals (NRC)
| Total Revenue | $140.00M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +4.00% |
| Gross Margin | +61.75% |
| Operating Margin | -0.22% |
| Profit Margin | +4.18% |
| ROE | +42.03% |
| Debt / Equity | 13.81 |
| Current Ratio | 0.65 |
| Total Cash | $3.33M |
| Total Debt | $90.45M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $21.64M (15.5% of revenue) |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financial Health Score (NRC)
Nexqual rates NRC Health's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 12:51 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Critical — $3M cash and investments vs $90M debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $22M (last 4 quarters to Jun 2026, SEC), 15% margin |
| Efficiency | Strong — ROE 42%, ROA 8.1% |
Ownership (NRC)
| Insider Ownership | +49.79% |
|---|---|
| Institutional Ownership | +51.17% |
| Shares Outstanding | 22.12M |
| Float | 11.82M |
| Short % of Float | +28.49% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Leadership (NRC)
NRC Health is led by Michael D. Hays, Founder & Chairman, per Nexqual as of October 23, 2026 at 12:51 UTC.
| Founder & Chairman | Michael D. Hays |
|---|---|
| EVP & COO | Helen L. Hrdy |
| Executive Vice President of Sales | Jason R. Rau |
| Executive Vice President of Strategic Insights | David Burik |
Major Backers & Investors (NRC)
Notable institutional backers of NRC Health include Kayne Anderson Rudnick Investment Management LLC, Virtus Equity Trust-Virtus KAR Small-Cap Growth Fund, Morgan Stanley, according to Nexqual as of October 23, 2026 at 12:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kayne Anderson Rudnick Investment Management LLC | 9.01% |
| Virtus Equity Trust-Virtus KAR Small-Cap Growth Fund | 4.1% |
| Morgan Stanley | 3.81% |
| Farmers & Merchants Investments Inc | 2.23% |
| Willis Investment Counsel | 1.91% |
| QV Investors Inc. | 1.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.71% |
| Vanguard Group | 2.96% |
| Dimensional Fund Advisors | 2.18% |
| Geode Capital | 1.86% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
From NRC Health's Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Our end-to-end solutions enable our customers to understand what matters most to each person they serve – before, during, after, and beyond clinical encounters – to gain a longitudinal understanding of each individual.
- Our approach includes engagement, pulse, lifecycle, Culture of Safety, and Magnet RN Satisfaction—plus employee rounding that encourages open conversations and uncovers insights beyond surveys alone.
- Embedded in our integrated experience platform, Huey helps customers make sense of experience data faster, taking on time-consuming tasks so teams can spend more time coaching, strategizing, and focusing on the human side of healthcare.
- Our platform includes features and capabilities built specifically for healthcare providers, including a library of performance improvement content which can be tailored to the provider based on their specific customer feedback profile.
Legal & Regulatory Risks (Item 1A, quoted)
- Failure to comply with public company regulations could adversely impact our profitability.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EVH | Evolent Health, Inc | USD 4.89 | ▲ 1.24% |
| CARL | Carlsmed, Inc. | USD 14.61 | ▲ 2.1% |
| CTEV | Claritev Corporation | USD 23.5 | ▲ 2.17% |
| WEAV | Weave Communications, Inc. | USD 7.39 | ▲ 0% |
| SOPH | SOPHiA GENETICS SA | USD 7.05 | ▼ 4.08% |
| PHR | Phreesia, Inc. | USD 12.72 | ▲ 3.75% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 12:51 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt